ArticleCurrent drug targets2026
Investigating Alternative Treatments for Dyslipidemia Using Bioactive Compounds Derived from Kiwifruit (Actinidia chinensis): A Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation Analysis.
Article in Current drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionKiwi has many bioactive compounds that may improve blood lipid levels and help treat dyslipidemia, but its molecular mechanism is not fully understood. This study explores these mechanisms using pharmacological network analysis.
methodsBioactive compounds of kiwi were obtained from the IMPPAT website, and molecular targets were identified using Swiss Target Prediction and PharmMapper. Genes associated with dyslipidemia were searched in the DISGENET database. Subsequently, an enrichment analysis was conducted, and a protein-protein interaction network was constructed. Hub genes were identified. Subsequently, a molecular docking analysis was performed, followed by a molecular dynamics simulation.
resultsSix bioactive compounds in kiwifruit showed good oral bioavailability and drug-likeness. Thirty-five genes linked to dyslipidemia and kiwi's targets were identified. Enrichment analysis highlighted the PPAR signaling pathway, lipid metabolism, and atherosclerosis. Hub genes included ALB, PPARG, AKT1, MMP9, PPARA, HMGCR, GSK3B, NOS3, PPARD, ACE, JAK2, and DPP4, with their interactions verified by molecular docking. Interactions between JAK2, ACE, and bioactive compounds (quinic acid and citric acid) involved spontaneous binding. Molecular dynamics simulations assessed conformational stability, mobility, solvation, and compaction of top-scoring protein-compound complexes. DISCUSSION: Bioactive compounds in kiwifruit can modulate dyslipidemia via PPAR pathways, JAK2, and ACE, supported by docking analyses and simulations. They show therapeutic potential, pending experimental validation.
conclusionOur findings suggest how kiwi affects dyslipidemia. In silico analysis is a first step in exploring food compounds like kiwi as potential alternative treatments.
Indexed as
Identifiers
41930644What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.